ERNA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.1M
-26.6%
5.6M
+167.0%
2.1M
+5.1%
2.0M
-20.3%
2.5M
R&D
2.8M
+45.8%
1.9M
+183.3%
676.0K
-34.7%
1.0M
-8.9%
1.1M
SG&A
1.3M
-19.6%
1.6M
+15.0%
1.4M
+48.0%
958.0K
-29.8%
1.4M
Operating Income
-4104000
+26.6%
-5590000
-167.0%
-2094000
-5.1%
-1993000
+20.3%
-2501000
EBITDA
-4095000
-15.7%
-3538000
-87.9%
-1883000
+4.7%
-1976000
+20.5%
-2484000
Net Income
-4009000
+27.2%
-5506000
-266.6%
-1502000
-21.1%
-1240000
+60.5%
-3139000
EPS (Basic)
$-3.40
+51.1%
$-6.95
-206.2%
$-2.27
+39.5%
$-3.75
+75.3%
$-15.19
EPS (Diluted)
$-3.40
+51.1%
$-6.95
-206.2%
$-2.27
+39.5%
$-3.75
+75.3%
$-15.19
Shares (Diluted)
1.2M
+49.4%
792.0K
+18.9%
666.1K
+102.4%
329.0K
+59.0%
207.0K
Ernexa Therapeutics (ERNA) โ€” Financials